期刊文献+

CRISPR-Cas9技术在医药领域中的应用 被引量:4

CRISPR-Cas9 and its application in medical field
下载PDF
导出
摘要 CRISPR-Cas9是存在于细菌和古细菌中的一种抵御噬菌体或质粒侵染的获得性免疫防御系统,它由成簇规律间隔短回文重复基因序列(clustered regularly interspaced short palindromic repeats,CRISPR)和Cas(CRISPR-associated)蛋白组成。天然的II型CRISPR系统已经被改造成第三代基因编辑工具,将单链向导RNA(single-guide RNA,sgRNA)和作为DNA内切酶的Cas9蛋白导入细胞内,即可在基因组特定位置上进行基因编辑。由于CRISPR-Cas9具有简便高效、脱靶效应低等特点,目前已被广泛应用在动物、植物、微生物的生理和病理研究以及药物研发等领域。本文着重讲述了CRISPR-Cas9的作用机制以及它在医药领域中的应用,包括构建生物模型、疾病治疗、药物靶点筛选和CRISPR与免疫疗法的联合应用。 CRISPR-Cas9 system,consisting of clustered regularly interspaced short palindromic repeats(CRISPR)and CRISPR-associated(Cas)proteins,is an acquired immune system that confers resistance to foreign genetic elements such as plasmids and phages.The natural type II CRISPR system has been transformed into a third-generation gene editing tool,which can conduct gene editing at specific positions in the genome by introducing single-strand guide RNA(sgRNA)and Cas9 protein as DNA endonuctase into cells.Due to its characteristics of simplicity,efficiency and relatively low off-target effect,CRISPR-Cas9 has been widely used in the physiological and pathological research of animals,plants and microorganisms as well as drug′s research and development.This review focuses on the mechanism of CRISPR-Cas9 and its application in the medical field,including the construction of biological models,disease treatment,drug target screening and its combination with immunotherapy.
作者 孙明尧 白玮 梁宏玉 赵秋蓉 张悦榕 徐慰倬 SUN Mingyao;BAI Wei;LIANG Hongyu;ZHAO Qiurong;ZHANG Yuerong;XUWeizhuo(School of Pharmacy,Shenyang Pharmaceutical University,Benxi 117004,China;School of Functional Food and Wine,Shenyang Pharmaceutical University,Benxi 117004,China)
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2019年第12期1145-1154,共10页 Journal of Shenyang Pharmaceutical University
基金 辽宁省教育厅基本科研项目(自然科学类)(2017LFW08).
关键词 CRISPR-Cas9 基因编辑 构建生物模型 药物靶点筛选 联用免疫疗法 CRISPR-Cas9 gene editing building biological models drug target screening combination with immunotherapy
  • 相关文献

参考文献7

二级参考文献52

  • 1Wiedenheft B, Sternberg SH, Doudna JA. Nature 2012; 482:331-338.
  • 2Terns MP, Terns RM. Curr Opin Microbiol20 11; 14:321-327.
  • 3Bhaya D, Davison M, Barrangou R. Ann Rev Genet 2011; 45:273-297.
  • 4Taylor GK, Heiter DF, Pietrokovski S, et al. Nucleic Acids Res 2011; 39:9705-9719.
  • 5Sapranauskas R, Gasiunas G, Fremaux C, et al. Nucleic Acids Res 2011; 39:9275-9282.
  • 6Makarova KS, Haft DH, Barrangou R, et al. Nat Rev Microbiol20ll; 9:467-477.
  • 7Makarova KS, Aravind L, WolfYl, et a1. Bioi Direct 2011; 6:38.
  • 8Makarova KS, Grishin NV, Shabalina SA, et al. Bioi Direct 2006; 1:7.
  • 9Jinek M, Chylinski K, Fonfara 1, et al. Science 2012; 337:816-82l.
  • 10Gasiunas G, Barrangou R, Horvath P, et al. Proc Natl Acad Sci USA 2012; 109:E2579-E2586.

共引文献287

同被引文献84

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部